Focus on Diabetes Care

Back to articles

New trial supports use of lixisenatide in older, nonfrail adults with type 2 diabetes


Use of once-daily lixisenatide (Adlyxin—Sanofi-Aventis) in older, nonfrail patients whose type 2 diabetes (T2D) was not controlled on their current antidiabetic regimen resulted in improvements in glycemic measures but was associated with higher rates of hypoglycemia and gastrointestinal (GI) adverse events, according to results of the GetGoal-O trial published in Diabetes Care.